Adults with dementia due to Alzheimer’s disease who experience agitation may be considered for Auvelity following its April 30, 2026, U.S. Food and Drug Administration approval. The indication does not impose a particular age, Mini-Mental State Examination score, or care setting, and the clinical-trial entry criteria are not mandatory prescribing rules. For example, an 82-year-old living at home who has Alzheimer’s dementia and persistent pacing, shouting, or physical resistance may be considered even if that person would not have qualified for the pivotal trials. Eligibility does not mean Auvelity is appropriate for every agitated adult with Alzheimer’s disease.
A clinician must confirm that the behavior is associated with Alzheimer’s dementia, investigate potentially reversible causes, review medications and medical risks, and decide whether regular drug treatment is justified. Someone who becomes suddenly combative because of an infection, pain, constipation, medication toxicity, or an unfamiliar environment may need treatment of that trigger rather than a new long-term agitation medication. The FDA describes Auvelity as the first approved treatment for agitation associated with Alzheimer’s dementia that is not an antipsychotic. It is an oral extended-release fixed combination of dextromethorphan hydrobromide and bupropion hydrochloride, available as 30 mg/105 mg and 45 mg/105 mg tablets. Importantly, it is not approved for occasional, as-needed use during isolated episodes of agitation.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Review FDA prescribing information for Auvelity — Verify the labeled indication, contraindications, screening needs, interactions, and dosing with a clinician.
- Read the FDA’s Auvelity approval announcement — Confirm the April 2026 approval and the evidence FDA considered for Alzheimer’s-related agitation.
Table of Contents
- Who May Be Eligible for Auvelity for Alzheimer’s Agitation After the 2026 Approval?
- How the Studied Population Differs From the FDA-Labeled Population
- What the Auvelity Agitation Trials Actually Found
- How Auvelity Is Started and Adjusted in Practice
- Common Eligibility Problems and Reasons to Pause
- Measuring Response Without Relying on a General Impression
- Questions for the Prescribing Visit
- Frequently Asked Questions
Who May Be Eligible for Auvelity for Alzheimer’s Agitation After the 2026 Approval?
The practical labeled population is broad: an adult who has dementia due to Alzheimer’s disease and agitation associated with that dementia. The indication itself does not specify a minimum agitation score, an MMSE range, an upper age limit, or whether the person must live at home, in assisted living, or in a nursing facility. Eligibility therefore begins with the diagnosis and clinical problem, not a checklist copied from a research protocol. A person with repeated verbal aggression, restlessness, hitting, grabbing, or resistance to essential care might be considered when the behavior causes distress, interferes with care, or creates safety concerns.
By comparison, ordinary forgetfulness, wandering without agitation, depression without agitation, or a single upset reaction would not automatically fit the approved use. Clinicians still need to determine what “agitation” means in the individual situation and whether medication is warranted. The fda approved the expanded use on April 30, 2026, specifically for “agitation associated with dementia due to Alzheimer’s disease in adults.” It was an approval, not merely acceptance of an application or publication of favorable trial findings. That distinction matters when families encounter older articles describing Auvelity as investigational for this use. FDA approval announcement.
How the Studied Population Differs From the FDA-Labeled Population
Participants in the pivotal trials had probable Alzheimer’s disease under the 2011 National Institute on Aging–Alzheimer’s Association criteria. They also had moderate-to-severe agitation requiring drug intervention, an MMSE score from 10 through 24, and a score of at least 4 on the agitation/aggression item of the Neuropsychiatric Inventory. These details describe the evidence base, but they are not automatic FDA requirements that every patient must satisfy. This difference is important for people outside the studied range. A patient with an MMSE score of 8, for example, is not expressly excluded by the indication, but the pivotal results provide less direct evidence for someone with that degree of cognitive impairment.
The same limitation applies to a younger adult with Alzheimer’s dementia or a person older than those enrolled. Prescribing in such cases requires more individualized judgment rather than assuming the trial results transfer perfectly. The acute trial’s median participant age was 75, with an age range of 65 to 90. Participants were 56% female, 86% White, 12% Black, and 1% Asian. The limited representation of some racial and ethnic populations affects how confidently clinicians can generalize the findings, especially when differences in medical conditions, medication exposure, and access to dementia care are not fully represented in the study population. FDA-approved trial information.
What the Auvelity Agitation Trials Actually Found
In the five-week randomized acute-efficacy trial, 152 participants received Auvelity and 156 received placebo. Scores on the Cohen-Mansfield Agitation Inventory, or CMAI, improved by 14.9 points with Auvelity and 11.6 points with placebo. The placebo-adjusted difference was −3.3 points, with a 95% confidence interval from −5.8 to −0.8. Both groups improved, which is an important limitation when interpreting the headline result.
The study supports an average additional benefit from Auvelity, but it does not mean every treated person improved by 14.9 points or that improvement was entirely attributable to the drug. For example, one resident may have a meaningful reduction in striking and shouting, while another may show little observable change despite following the same dosing schedule. The second randomized trial examined maintenance of response rather than initial success in all new patients. Participants first received Auvelity, and only those who achieved a sustained response were randomized either to continue it or switch to placebo. Continuing treatment significantly prolonged the time to relapse, but this enriched withdrawal design cannot establish that every person starting Auvelity will become a responder.
How Auvelity Is Started and Adjusted in Practice
For Alzheimer’s agitation, labeled dosing begins with one 30 mg/105 mg tablet each morning. After day 8, the dose may increase to 30 mg/105 mg twice daily if tolerated. After day 15, it may increase to as much as 45 mg/105 mg twice daily, with doses separated by at least eight hours. The gradual schedule gives clinicians and caregivers time to watch for tolerability problems before reaching the highest labeled dose. This is scheduled treatment, not a rescue medication.
A caregiver should not give an extra tablet during an afternoon outburst or reserve the medication only for difficult bathing days. That differs from a PRN approach in which a drug is administered only when a symptom appears; the approved labeling specifically states that Auvelity is not indicated for as-needed treatment of agitation. Some patients require a lower once-daily regimen, including those with moderate renal impairment, those taking a strong CYP2D6 inhibitor, and known CYP2D6 poor metabolizers. A practical medication review should include prescriptions, over-the-counter products, and drugs prescribed by other clinicians because bupropion affects drug metabolism and the combination may not fit safely into every regimen. FDA-approved prescribing information.
Common Eligibility Problems and Reasons to Pause
A sudden change in behavior should not automatically be labeled Alzheimer’s agitation. Delirium, pain, urinary retention, constipation, dehydration, sleep disruption, infection, medication changes, and frightening care interactions can all present as restlessness or aggression. If a usually calm person becomes severely agitated over several hours, urgent assessment of the new change may be more appropriate than assuming the dementia has progressed. Diagnostic boundaries also matter.
The approval concerns agitation associated with dementia due to Alzheimer’s disease; it does not by itself establish the drug as approved for agitation caused by Lewy body dementia, frontotemporal dementia, vascular dementia, bipolar disorder, substance use, or an acute medical illness. Mixed dementia can make the decision less straightforward, particularly when clinicians are uncertain how much Alzheimer’s pathology contributes to the symptoms. Medication suitability requires more than matching the indication. The prescriber should review the complete FDA label, current medicines, kidney function, relevant medical and psychiatric history, and the person’s ability to take extended-release tablets reliably. Families should not substitute Auvelity for another medication, split the dosing schedule on their own, or assume that its non-antipsychotic status means it is risk-free.
Measuring Response Without Relying on a General Impression
Before treatment, caregivers can document specific behaviors, their frequency, timing, severity, triggers, and consequences. For example, “agitated most evenings” is less useful than recording that the person shouted during four of seven evening care sessions, struck a caregiver twice, and paced for 45 minutes after dinner. The same observations can be repeated after dose changes to help distinguish improvement from day-to-day fluctuation.
In the maintenance study, sustained response required at least a five-point improvement on the CMAI plus improvement on the Patient Global Impression of Change maintained for at least four weeks. Relapse included a CMAI worsening of at least 10 points, worsening beyond the pretreatment score for two consecutive weeks, or hospitalization or institutionalization because of agitation. Those research definitions are not mandatory home-monitoring rules, but they illustrate why a single calm or difficult day is inadequate for judging response.
Questions for the Prescribing Visit
Families can bring a current medication list, a timeline of the agitation, recent medical changes, and several concrete behavior examples. Useful questions include whether the behavior is consistent with Alzheimer’s agitation, which reversible causes have been checked, what improvement would justify continued treatment, what adverse changes require a call, and when response will be reassessed. For someone taking a strong CYP2D6 inhibitor or living with moderate renal impairment, the visit should also address the label’s lower once-daily regimen.
The treatment plan should identify who will administer each dose and how the eight-hour minimum interval will be maintained if twice-daily dosing is used. For example, a family might schedule doses for 8 a.m. and 4 p.m., record each administration, and contact the prescriber rather than doubling a dose after an error.
Frequently Asked Questions
Does a person need an MMSE score between 10 and 24 to receive Auvelity for Alzheimer’s agitation?
No. That range describes participants in the pivotal trials, not a mandatory restriction in the FDA indication. Evidence is less direct for patients outside the studied range, so clinicians must use individualized judgment.
Is Auvelity approved for people living in nursing homes?
The indication does not restrict treatment by care setting. An adult may be considered whether living at home, in assisted living, or in a nursing facility, provided the agitation is associated with dementia due to Alzheimer’s disease and treatment is clinically appropriate.
Can Auvelity be given only during an agitation episode?
No. It is not indicated for PRN or as-needed treatment. The Alzheimer’s-agitation regimen uses scheduled dosing with gradual increases when tolerated.
Is Auvelity an antipsychotic?
No. It is an extended-release combination of dextromethorphan hydrobromide and bupropion hydrochloride. The FDA describes it as the first approved non-antipsychotic treatment for agitation associated with Alzheimer’s dementia.
Did everyone in the clinical trials respond?
No. Trial results report average differences between groups. The maintenance trial included only people who first achieved a sustained response on Auvelity, so its relapse findings should not be interpreted as proof that every newly treated patient will respond.
